Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis
- Study Title
- Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to ClinicFemale, Maley Definite Multiple Sclerosis of Subjects Presenting With ClinicFemale, Maley Isolated Syndrome
- Teva Identifier
- GA 9010
- ClinicalTrials.gov Identifier
- NCT00666224
- Study Status
- Completed
- Trial Condition(s)
- Multiple Sclerosis
- Interventions
- Drug: Glatiramer Acetate (DB)|Drug: Placebo | Drug: Glatiramer Acetate (OL)
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult
- Age Range
- 18 Years to 45 Years
- Trial Duration
- 01/01/2004 - 06/01/2010
- Phase
- Phase 3
